Related Experiment Video
Updated: Aug 7, 2026
06:49
Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians
Published on: March 14, 2014
Nitroimidazole-resistant vaginal trichomoniasis treated with paromomycin
1Department of Gynaecology, University Hospital Gasthuisberg, Catholic University Leuven, Herestraat 49, B-3000, Leuven, Belgium. willy.poppe@uz.kuleven.ac.be
Summary
A patient with resistant vaginal trichomoniasis was treated with intravaginal paromomycin, achieving a cure but causing severe local side effects. Further research is needed to determine optimal paromomycin dosage for difficult cases.
Area of Science:
- Infectious Diseases
- Pharmacology
- Gynecology
Background:
- Vaginal trichomoniasis is a common sexually transmitted infection.
- Nitroimidazole drugs are the standard treatment for Trichomonas vaginalis vaginitis.
- Treatment failures due to drug resistance are an increasing concern.
Observation:
- A case study of a 33-year-old woman with recurrent vaginal trichomoniasis resistant to nitroimidazole therapy.
- The patient received intravaginal paromomycin 500 mg daily for 2 days.
Findings:
- Intravaginal paromomycin successfully eradicated Trichomonas vaginalis infection.
- The treatment resulted in severe local side effects, indicating a need for dosage optimization.
- Paromomycin demonstrates potential utility in managing challenging, drug-resistant cases.
Implications:
- Paromomycin may offer an alternative therapeutic option for patients with refractory vaginal trichomoniasis.
- Further clinical trials are warranted to establish the safety and efficacy profile of intravaginal paromomycin.
- Optimizing paromomycin dosage and administration is crucial to mitigate local side effects and improve patient tolerability.
Related Concept Videos
01:16Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
01:18Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
01:30Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care
A healthcare provider can diagnose a urinary tract infection (UTI) through several methods:Medical History and Symptoms: The provider will take a detailed medical history and ask about symptoms such as frequent urination, burning sensation during urination, and lower abdominal pain.Urinalysis: A clean-catch urine sample is collected in a sterile container and tested for the presence of bacteria, white blood cells (leukocytes), nitrites, blood, and protein. The presence of leukocytes and...
01:18Trichomoniasis
Trichomonas vaginalis is a flagellated protozoan parasite and the causative agent of trichomoniasis, one of the most prevalent non-viral sexually transmitted infections in the United States. This extracellular parasite primarily colonizes the lower genitourinary tract in women—particularly the vagina—and in men, the urethra and prostate. Its structural and functional adaptations enable its survival, motility, and pathogenicity within the host environment.Structural Features and Host EntryT.
01:15Anthelminthic Agents
Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
01:21Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...